Peripheral Vasodilator Drugs Market Size, Share, Major Players, Business Strategies, Opportunities And Forecast To 2033
Share this Post to earn Money ( Upto ₹100 per 1000 Views )
Overview and Scope
The peripheral vasodilator drugs market consists of sales of angiotensin II receptor blockers (ARBs), nitric oxide donors, direct renin inhibitors, and endothelin receptor antagonists. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Sizing and Forecast
The peripheral vasodilator drugs market size has grown strongly in recent years. It will grow from $5.92 billion in 2023 to $6.27 billion in 2024 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to the shift towards less invasive surgical techniques, the demand for minimally invasive structural heart devices, ongoing training and education programs for healthcare professionals, rising healthcare expenditure, and growing patient preference for non-surgical or minimally invasive treatment options.
The peripheral vasodilator drugs market size is expected to see strong growth in the next few years. It will grow to $7.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the increasing aging population, growing awareness about heart health, the implementation of screening programs, favorable reimbursement policies for structural heart procedures, and timely regulatory approvals for new structural heart devices. Major trends in the forecast period include increased collaboration, real-world evidence, gene therapy, preventive interventions, and value-based healthcare.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report
Segmentation & Regional Insights
The peripheral vasodilator drugs market covered in this report is segmented –
1) By Drug Type: Calcium Channel Blockers, Direct-Acting Vasodilators, Alpha-Adrenergic Blockers, Potassium Channel Activators, Nitrates, Other Types
2) By Indication: Hypertension, Angina, Heart Failure, Other Indications
3) By Application: Hospital, Retail Pharmacies, Other Applications
North America was the largest region in the peripheral vasodilator drugs market in 2023. The regions covered in the peripheral vasodilator drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16508&type=smp
Major Driver Impacting Market Growth
An increase in the prevalence of cardiovascular diseases is expected to propel the growth of the peripheral vasodilator drug market going forward. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, often caused by atherosclerosis, leading to conditions like heart attacks, strokes, hypertension, and heart failure. The cases of cardiovascular diseases arise primarily due to sedentary lifestyles, unhealthy diets, aging populations, rising rates of obesity, and related health conditions such as diabetes and hypertension. Peripheral vasodilators in cardiovascular diseases improve blood flow, reduce blood pressure, decrease the heart’s workload, and alleviate symptoms of conditions such as peripheral arterial disease. For instance, in January 2024, according to an article published by the American Heart Association, a US-based nonprofit organization focused on cardiovascular medical research, cardiovascular disease caused 931,578 deaths in the US, slightly more than the 928,741 in 2020. Globally, there were 19.91 million CVD deaths in 2021, compared to 19.05 million in 2020. Therefore, the increase in the prevalence of cardiovascular diseases is driving the growth of the peripheral vasodilator drug market.
Key Industry Players
Major companies operating in the peripheral vasodilator drugs market are Pfizer Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company, Gilead Sciences Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Merck & Co, Viatris Inc., Baxter, Teva Pharmaceutical Industries, Astellas Pharma, Daiichi Sankyo Company, Limited, Sun Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Cipla Limited, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals, Ipca Laboratories, Alembic Pharmaceuticals
The peripheral vasodilator drugs market report table of contents includes:
1. Executive Summary
2. Peripheral Vasodilator Drugs Market Characteristics
3. Peripheral Vasodilator Drugs Market Trends And Strategies
4. Peripheral Vasodilator Drugs Market - Macro Economic Scenario
5. Global Peripheral Vasodilator Drugs Market Size and Growth
...
32. Global Peripheral Vasodilator Drugs Market Competitive Benchmarking
33. Global Peripheral Vasodilator Drugs Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Peripheral Vasodilator Drugs Market
35. Peripheral Vasodilator Drugs Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model